alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,751–1,775 of 3,088 studies · tagged Treatments (page 71 of 124) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Effect of Potentially Inappropriate Use of Antimuscarinic Medications on Healthcare Use and Cost in Individuals with Overactive Bladder

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of the American Geriatrics Society 2016-04-01

Of members initiated on an antimuscarinic OAB medication, 31.1% had a drug-drug or drug-disease or syndrome interaction. 5 key findings →

Participants: 66,275 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Diabetes 2018-06-22

For patients with serious comorbidities, diabetes management guidelines recommend more relaxed glycemic targets (glycosylated hemoglobin [HbA1c] <8-8.5% rather than <7%) and cautious use of agents known to cause hypoglycemia. 5 key findings →

Participants: 216,839 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Factors associated with delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation

✓ Peer-reviewed alzhub usefulness score 41 out of 100. European Heart Journal 2023-11-01

In this study on Medicare patients with AF, Black race, low-income subsidy, and dual eligibility were found to be associated with delayed OAC initiation, suggesting potential disparities in the care of AF with timely OAC treatment. 5 key findings →

Participants: 446,441 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

ASHP Statement on the Pharmacist’s Role in Substance Use Disorder Prevention, Treatment, and Recovery

✓ Peer-reviewed alzhub usefulness score 41 out of 100. American Journal of Health-System Pharmacy 2026-02-19

In both adolescents and adults with SUD, approximately 95% did not perceive a need for treatment.1 Although drug-related overdose deaths are declining, over 98,000 American deaths occurred in 2024.2 The vast majority of drug overdose deaths involve unregulated opioids, and in 2022 roughly 6.1 million people had an opioid use disorder (OUD) in the prior year.1 Costs related to the consequences of substance use the United States were nearly $1.5 trillion in 2020, up 37% from $1.07 trillion in 2017.3,4 Unhealthy substance use and untreated SUD may increase the risk of significant comorbid chronic health conditions, death from overdose, or suicide. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Relationship between APOE Genotype Status and Imaging Features in Patients with Alzheimer Disease Being Considered for Antiamyloid β Therapy

✓ Peer-reviewed alzhub usefulness score 41 out of 100. American Journal of Neuroradiology 2026-03-01

A total of 85 patients were included in the study with rare genotypes excluded from analysis (3 patients). 5 key findings →

Participants: 85 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer Disease: Intersocietal Recommendations for Their Appropriate Use in Switzerland

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurodegenerative Diseases 2025-04-14

The association of Swiss Memory Clinics (SMC) provides intersocietal recommendations for the use of anti-amyloid monoclonal antibodies (mAbs) in Switzerland. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer Combination Therapies: Overview and Scenarios

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-10-27

Progress in understanding the complexity of Alzheimer's disease informs the search for combination therapies that can successfully prevent or substantially slow the progression of the disease. 5 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience Grows

✓ Peer-reviewed alzhub usefulness score 41 out of 100. JAMA 2025-08-22

This Medical News article discusses the safety and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-07-13

Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Anti-pyroglutamate-3 Aβ immunotherapy engages microglia and inhibits amyloid accumulation in transgenic mouse models of Aβ amyloidosis

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Acta Neuropathologica 2025-06-02

Alzheimer disease (AD) is the most common form of dementia affecting more than 6 million people in the United States. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence–Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration

✓ Peer-reviewed alzhub usefulness score 41 out of 100. American Journal of Roentgenology 2026-09-16

Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Preliminary efficacy of an online intervention based on Acceptance and Commitment Therapy for family caregivers of people with dementia: a feasibility study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cognitive Behaviour Therapy 2025-03-27

With the rising number of dementia cases, supporting family caregivers to maintain their well-being is crucial. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Molecular Neurodegeneration 2025-07-01

Dementia with Lewy bodies (DLB) is thought to be the second most common form of dementia after Alzheimer’s disease, and is characterised by a combination of cognitive, neuropsychiatric and motor symptoms. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Single-Cell Transcriptomic Identification of SYK Kinase as a Therapeutic Target in Disease-Associated Microglia for Alzheimer's Disease Treatment

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-03-23

Alzheimer's disease (AD) affects over 55 million people worldwide and lacks effective disease-modifying therapies targeting neuroinflammation. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer s Disease 2025-03-28

BackgroundAlzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

From across this tag

9 of the 3,071 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed